Results 181 to 190 of about 228,627 (303)

Discovery of pan-VEGF inhibitory peptides directed to the extracellular ligand-binding domains of the VEGF receptors. [PDF]

Sci Adv, 2016
Michaloski JS, Redondo AR, Magalhães LS, Cambui CC, Giordano RJ.   +4 more
europepmc   +1 more source

Opinion: Inhibition of Blood-Brain Barrier Repair as a Mechanism in HIV-1 Disease. [PDF]

, 2017
Maubert, Monique E., Nonnemacher, Michael R., Wigdahl, Brian   +2 more
core   +2 more sources

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

Advanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang, Xuan Wang, Xinfeng Dai, Linxin Tian, Wencheng Shen, Xueliang Liu, Wei Xue, Jiahua Pan, Yu Yang   +8 more
wiley   +1 more source

Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells. [PDF]

Sci Rep, 2017
Momeny M, Sabourinejad Z, Zarrinrad G, Moghaddaskho F, Eyvani H, Yousefi H, Mirshahvaladi S, Poursani EM, Barghi F, Poursheikhani A, Dardaei L, Bashash D, Ghazi-Khansari M, Tavangar SM, Dehpour AR, Yaghmaie M, Alimoghaddam K, Ghavamzadeh A, Ghaffari SH.   +18 more
europepmc   +1 more source

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

Advanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang, Kejia Li, Ning Wang, Zhen Li, Zhiyong Zhang, Rocky S. Tuan, Yangzi Jiang   +6 more
wiley   +1 more source

VEGF and Neurotrophins Interaction in the Retinal Neurovascular Unit Homeostasis: A Target for Ocular Disease Treatment and Management. [PDF]

Pharm Res
Di Criscio A, Rosso P, Fico E, Iannetta D, Marenco M, Lambiase A, Tirassa P.   +6 more
europepmc   +1 more source

Multifunctional Bioactive Scaffold Facilitating BMSCs‐Driven Osteogenesis and Vascularization in Critical‐Sized Bone Defect Repair

Advanced Science, EarlyView.
A dual‐network bFGF@CB‐gel integrates: i) ChSMA scaffold (mechanical support/BMSCs delivery); ii) BC carrier (sustained bFGF release via EGFL/Itga2b and COMP/PI3K/AKT for adhesion/osteogenesis); iii) bFGF/PI3K/AKT/eNOS for angiogenesis. This rational, synergistic design addresses CSD bone regeneration challenges.
Yunze Feng, Bingzhi Chen, Yu Xu, Xin Xu, Bingtao Hu, Tongbo Li, Dingxin Zhang, Baoshuai Bai, Chen Liu, Wanlong Xu, Le Li, Wencan Zhang, Haipeng Si   +12 more
wiley   +1 more source

Ocular pharmacokinetics of tivozanib eye drops in patients with neovascular age-related macular degeneration: comparison with phase 1 trials of oral tivozanib in solid tumors. [PDF]

Int J Retina Vitreous
Horita S, Saki M, Takigawa S, Kanai Y, Murotani K, Gomi F.   +5 more
europepmc   +1 more source

S100A14 in Tumor‐Derived EVs Targets PIAS3 to Reprogram Astrocytes and Induce Immunosuppressive Microenvironment Promoting Brain Metastasis and Germacrone Reversal Effect

Advanced Science, EarlyView.
This study identifies S100A14 in tumor‐derived exosomes as a key driver of brain metastasis. S100A14 targets PIAS3 in astrocytes, activating STAT3 signaling and promoting immunosuppressive MDSCs recruitment via chemokine secretion. Germacrone, a natural compound, binds S100A14 to disrupt this axis, effectively inhibiting brain metastasis with low ...
Qian Feng, Xia Yang, Lin An, Xue‐Yu Wang, Ming‐Rui Wang, Zhuo‐Hong Cai, Cai‐Jun Xie, Li‐Jun Qiao, You‐Bi Shen, Xi‐Min Liang, Rong Zhang, Cai‐Yan Wang, Zhong‐Qiu Liu, Rong‐Rong Zhang   +13 more
wiley   +1 more source

Advances in semaphorin 3B research in tumors (Review). [PDF]

Mol Clin Oncol
Zhang X, Feng R, Zhao H, Wei J, Xu X.
europepmc   +1 more source